AHNAK Inhibitors
AHNAK inhibitors comprise a specialized pharmacological arsenal strategically designed to selectively intervene in the complex signaling pathways governing AHNAK expression and function. These chemical agents are tailored to target specific molecular players, effectively disrupting key pathways intricately involved in the regulation of AHNAK. Notably, inhibitors of the TGF-β receptor, such as SB431542, LY364947, A83-01, SD-208, LY2157299, and RepSox, operate indirectly by impeding TGF-β-dependent pathways crucial for AHNAK control. By doing so, these inhibitors perturb the delicate balance of signaling events that converge on AHNAK expression, providing invaluable tools for researchers to dissect the intricate regulatory networks orchestrating AHNAK-mediated responses.
In a parallel approach, MEK inhibitors, including U0126, PD98059, SL327, AZD6244, PD0325901, and Trametinib, exert their inhibitory effects by specifically targeting the MAPK/ERK pathway-a pivotal player in the regulation of AHNAK. Through disruption of this pathway, these inhibitors finely modulate the intricate network of signaling events converging on AHNAK, offering a targeted and focused strategy to inhibit AHNAK-mediated responses. The combined action of these inhibitors forms an indispensable toolkit for researchers dedicated to unraveling the complexity of AHNAK regulation. By utilizing these pharmacological tools, scientists contribute to a deeper and more nuanced understanding of AHNAK's multifaceted role in various cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, SB431542 hinders downstream events, including the regulation of AHNAK. The TGF-β pathway has been implicated in the control of AHNAK expression, and SB431542's impact on TGF-β signaling provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947, a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, LY364947 hinders downstream events, including the regulation of AHNAK. The TGF-β pathway has been implicated in the control of AHNAK expression, and LY364947's impact on TGF-β signaling provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly influences AHNAK by targeting the MAPK/ERK pathway. By inhibiting MEK, PD98059 disrupts downstream events, including the regulation of AHNAK. The MAPK/ERK pathway has been implicated in the control of AHNAK expression, and PD98059's impact on this pathway provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01, a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, A83-01 hinders downstream events, including the regulation of AHNAK. The TGF-β pathway has been implicated in the control of AHNAK expression, and A83-01's impact on TGF-β signaling provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327, a MEK inhibitor, indirectly influences AHNAK by targeting the MAPK/ERK pathway. By inhibiting MEK, SL327 disrupts downstream events, including the regulation of AHNAK. The MAPK/ERK pathway has been implicated in the control of AHNAK expression, and SL327's impact on this pathway provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-β RI Kinase Inhibitor V (SD-208), a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, SD-208 hinders downstream events, including the regulation of AHNAK. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, indirectly influences AHNAK by targeting the MAPK/ERK pathway. By inhibiting MEK, AZD6244 disrupts downstream events, including the regulation of AHNAK. The MAPK/ERK pathway has been implicated in the control of AHNAK expression, and AZD6244's impact on this pathway provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299, a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, LY2157299 hinders downstream events, including the regulation of AHNAK. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
ALK5 Inhibitor II (RepSox), a TGF-β receptor inhibitor, indirectly modulates AHNAK by disrupting TGF-β-dependent pathways. By inhibiting TGF-β receptors, RepSox hinders downstream events, including the regulation of AHNAK. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor, indirectly influences AHNAK by targeting the MAPK/ERK pathway. By inhibiting MEK, Trametinib disrupts downstream events, including the regulation of AHNAK. The MAPK/ERK pathway has been implicated in the control of AHNAK expression, and Trametinib's impact on this pathway provides an indirect mechanism for inhibiting AHNAK-mediated responses by modulating the intricate network of signaling pathways that converge on AHNAK expression. | ||||||